{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:09:34Z","timestamp":1762495774751,"version":"build-2065373602"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,6]]},"DOI":"10.7759\/cureus.96266","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:05:59Z","timestamp":1762495559000},"source":"Crossref","is-referenced-by-count":0,"title":["Tumor-Infiltrating Lymphocytes and Tumor Budding: Emerging Prognostic Markers in Breast Cancer"],"prefix":"10.7759","author":[{"given":"Naincy","family":"Rastogi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shreshtha","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priyanka","family":"Sameer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepti","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priyadarshini","family":"Guha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3233\/BD-200442","article-title":"Evaluation of tumor infiltrating lymphocytes in breast carcinoma and their correlation with molecular subtypes, tumor grade and stage","volume":"39","author":"Pujani M","year":"2020","unstructured":"Pujani M, Jain H, Chauhan V, Agarwal C, Singh K, Singh M. Evaluation of tumor infiltrating lymphocytes in breast carcinoma and their correlation with molecular subtypes, tumor grade and stage. Breast Dis. 2020, 39:61-9. 10.3233\/BD-200442","journal-title":"Breast Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.287","article-title":"The relationship between tumour budding, the tumour microenvironment and survival in patients with invasive ductal breast cancer","volume":"113","author":"Gujam FJ","year":"2015","unstructured":"Gujam FJ, McMillan DC, Mohammed ZM, Edwards J, Going JJ. The relationship between tumour budding, the tumour microenvironment and survival in patients with invasive ductal breast cancer. Br J Cancer. 2015, 113:1066-74. 10.1038\/bjc.2015.287","journal-title":"Br J Cancer"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2020.1130","article-title":"The prognostic influence of tumour budding in Western patients with stage II colorectal cancer","volume":"14","author":"Cangu\u00e7u AL","year":"2020","unstructured":"Cangu\u00e7u AL, Val\u00e9rio E, Peixoto RB, et al.. The prognostic influence of tumour budding in Western patients with stage II colorectal cancer. Ecancermedicalscience. 2020, 14:1130. 10.3332\/ecancer.2020.1130","journal-title":"Ecancermedicalscience"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqy069","article-title":"Tumor-infiltrating lymphocytes in breast cancer: evaluating interobserver variability, heterogeneity, and fidelity of scoring core biopsies","volume":"150","author":"Khoury T","year":"2018","unstructured":"Khoury T, Peng X, Yan L, Wang D, Nagrale V. Tumor-infiltrating lymphocytes in breast cancer: evaluating interobserver variability, heterogeneity, and fidelity of scoring core biopsies. Am J Clin Pathol. 2018, 150:441-50. 10.1093\/ajcp\/aqy069","journal-title":"Am J Clin Pathol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu450","article-title":"The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014","volume":"26","author":"Salgado R","year":"2015","unstructured":"Salgado R, Denkert C, Demaria S, et al.. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015, 26:259-71. 10.1093\/annonc\/mdu450","journal-title":"Ann Oncol"},{"key":"ref6","article-title":"Effect of tumor budding and tumor infiltrating lymphocytes on prognosis of colorectal mucinous adenocancers","volume":"8","author":"Cabuk FK","year":"2019","unstructured":"Cabuk FK, Sakiz D, Ozer EE, Kahraman ZS. Effect of tumor budding and tumor infiltrating lymphocytes on prognosis of colorectal mucinous adenocancers. Med Sci Int Med J. 2019, 8:896-900.","journal-title":"Med Sci Int Med J"},{"key":"ref7","article-title":"Tumor infiltrating lymphocytes (TILs) and tumor budding in invasive breast carcinoma: correlation with known prognostic parameters","volume":"10","author":"Bandyopadhyay A","year":"2023","unstructured":"Bandyopadhyay A, Krishna MP. Tumor infiltrating lymphocytes (TILs) and tumor budding in invasive breast carcinoma: correlation with known prognostic parameters. Arch Breast Cancer. 2023, 10:241-7.","journal-title":"Arch Breast Cancer"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/PAP.0000000000000162","article-title":"Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immunooncology Biomarkers Working Group: part 1: assessing the host immune response, TILs in invasive breast carcinoma and ductal carcinoma in situ, metastatic tumor deposits and areas for further research","volume":"24","author":"Hendry S","year":"2017","unstructured":"Hendry S, Salgado R, Gevaert T, et al.. Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immunooncology Biomarkers Working Group: part 1: assessing the host immune response, TILs in invasive breast carcinoma and ductal carcinoma in situ, metastatic tumor deposits and areas for further research. Adv Anat Pathol. 2017, 24:235-51. 10.1097\/PAP.0000000000000162","journal-title":"Adv Anat Pathol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-021-00346-1","article-title":"The tale of TILs in breast cancer: a report from the International Immuno-Oncology Biomarker Working Group","volume":"7","author":"El Bairi K","year":"2021","unstructured":"El Bairi K, Haynes HR, Blackley E, et al.. The tale of TILs in breast cancer: a report from the International Immuno-Oncology Biomarker Working Group. NPJ Breast Cancer. 2021, 7:150. 10.1038\/s41523-021-00346-1","journal-title":"NPJ Breast Cancer"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1159\/000444357","article-title":"Tumor-infiltrating lymphocytes: a promising biomarker in breast cancer","volume":"11","author":"Ingold Heppner B","year":"2016","unstructured":"Ingold Heppner B, Loibl S, Denkert C. Tumor-infiltrating lymphocytes: a promising biomarker in breast cancer. Breast Care (Basel). 2016, 11:96-100. 10.1159\/000444357","journal-title":"Breast Care (Basel)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/nature21349","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen DS","year":"2017","unstructured":"Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017, 541:321-30. 10.1038\/nature21349","journal-title":"Nature"},{"key":"ref12","article-title":"A study of clinicopathological significance of tumour budding in breast carcinoma","volume":"13","author":"Buch AC","year":"2022","unstructured":"Buch AC, Jain K, Rathod H, Gore C. A study of clinicopathological significance of tumour budding in breast carcinoma. J Pharm Negat Results. 2022, 13:8069-81.","journal-title":"J Pharm Negat Results"},{"key":"ref13","article-title":"Evaluation of prognostic role of tumour budding in breast carcinoma and its correlation with known clinicopathological parameters","volume":"9","author":"Patel M","year":"2022","unstructured":"Patel M, Gupta V. Evaluation of prognostic role of tumour budding in breast carcinoma and its correlation with known clinicopathological parameters. Indian J Pathol Oncol. 2022, 9:238-42.","journal-title":"Indian J Pathol Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.34172\/ipp.2022.31365","article-title":"Tumor budding in gastric adenocarcinoma: reflections on tumor microenvironment and programmed death ligand 1 (PD-L1) expression","volume":"9","author":"Abd El Khalek SM","year":"2023","unstructured":"Abd El Khalek SM, Halim MI. Tumor budding in gastric adenocarcinoma: reflections on tumor microenvironment and programmed death ligand 1 (PD-L1) expression. Immunopathol Persa. 2023, 9:e31365. 10.34172\/ipp.2022.31365","journal-title":"Immunopathol Persa"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.4103\/IJPM.IJPM_120_18","article-title":"Tumor budding in infiltrating breast carcinoma: correlation with known clinicopathological parameters and hormone receptor status","volume":"62","author":"Agarwal R","year":"2019","unstructured":"Agarwal R, Khurana N, Singh T, Agarwal PN. Tumor budding in infiltrating breast carcinoma: correlation with known clinicopathological parameters and hormone receptor status. Indian J Pathol Microbiol. 2019, 62:222-5. 10.4103\/IJPM.IJPM_120_18","journal-title":"Indian J Pathol Microbiol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1055\/s-0042-1747676","article-title":"A retrospective study of association of tumor budding, tumor microenvironment, and clinicopathological characteristics of invasive breast carcinoma","volume":"14","author":"Singh T","year":"2022","unstructured":"Singh T, Chandra K, Kumar N, et al.. A retrospective study of association of tumor budding, tumor microenvironment, and clinicopathological characteristics of invasive breast carcinoma. J Lab Physicians. 2022, 14:485-90. 10.1055\/s-0042-1747676","journal-title":"J Lab Physicians"},{"key":"ref17","doi-asserted-by":"crossref","DOI":"10.33545\/pathol.2019.v2.i1c.25","article-title":"Evaluation of clinicopathologic significance of tumor budding in breast carcinoma","volume":"2","author":"Masilamani S","year":"2019","unstructured":"Masilamani S, Kanmani P. Evaluation of clinicopathologic significance of tumor budding in breast carcinoma. Int J Clin Diagn Pathol. 2019, 2:171-3.","journal-title":"Int J Clin Diagn Pathol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10040827","article-title":"Prognostic role of tumor budding in breast cancer patients receiving neo-adjuvant therapy","volume":"10","author":"Mozarowski P","year":"2021","unstructured":"Mozarowski P, Rasaiah B, Reed M, Lewis A, Walde N, Voutsadakis IA. Prognostic role of tumor budding in breast cancer patients receiving neo-adjuvant therapy. J Clin Med. 2021, 10:827. 10.3390\/jcm10040827","journal-title":"J Clin Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.29637","article-title":"Correlation of tumor budding with known clinicopathological, histomorphological and hormonal receptor status in patients with invasive breast carcinoma","volume":"14","author":"Rathod GB","year":"2022","unstructured":"Rathod GB, Desai KN, Shrivastava A, Maru AM. Correlation of tumor budding with known clinicopathological, histomorphological and hormonal receptor status in patients with invasive breast carcinoma. Cureus. 2022, 14:e29637. 10.7759\/cureus.29637","journal-title":"Cureus"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-015-3333-3","article-title":"High tumor budding stratifies breast cancer with metastatic properties","volume":"150","author":"Salhia B","year":"2015","unstructured":"Salhia B, Trippel M, Pfaltz K, et al.. High tumor budding stratifies breast cancer with metastatic properties. Breast Cancer Res Treat. 2015, 150:363-71. 10.1007\/s10549-015-3333-3","journal-title":"Breast Cancer Res Treat"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.anndiagpath.2021.151792","article-title":"Tumor budding is a reliable predictor for death and metastasis in invasive ductal breast cancer and correlates with other prognostic clinicopathological parameters","volume":"54","author":"Okcu O","year":"2021","unstructured":"Okcu O, \u00d6zt\u00fcrk \u00c7, \u015een B, Arpa M, Bedir R. Tumor budding is a reliable predictor for death and metastasis in invasive ductal breast cancer and correlates with other prognostic clinicopathological parameters. Ann Diagn Pathol. 2021, 54:151792. 10.1016\/j.anndiagpath.2021.151792","journal-title":"Ann Diagn Pathol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0192744","article-title":"A new method for evaluating tumor-infiltrating lymphocytes (TILs) in colorectal cancer using hematoxylin and eosin (H-E)-stained tumor sections","volume":"13","author":"Iseki Y","year":"2018","unstructured":"Iseki Y, Shibutani M, Maeda K, et al.. A new method for evaluating tumor-infiltrating lymphocytes (TILs) in colorectal cancer using hematoxylin and eosin (H-E)-stained tumor sections. PLoS One. 2018, 13:e0192744. 10.1371\/journal.pone.0192744","journal-title":"PLoS One"},{"key":"ref23","article-title":"The significance of tumor-infiltrating lymphocytes (TILs) in histopathological grading of invasive breast carcinomas","volume":"60","author":"Syam R","year":"2021","unstructured":"Syam R, Miskad UA, Zainuddin AA, Sungowati NK, Arsyadi G, Nelwan B. The significance of tumor-infiltrating lymphocytes (TILs) in histopathological grading of invasive breast carcinomas. International Journal of Sciences: Basic and Applied Research. 2021, 60:115-22.","journal-title":"International Journal of Sciences: Basic and Applied Research"},{"key":"ref24","doi-asserted-by":"crossref","DOI":"10.3390\/app11156788","article-title":"Histopathological evaluation of tumor-infiltrating lymphocytes (TILs) as predictive biomarker for hormone receptor status, proliferative activity and clinical outcome in Her2-positive breast cancer","volume":"11","author":"Angelico G","year":"2021","unstructured":"Angelico G, Broggi G, Caltabiano R, et al.. Histopathological evaluation of tumor-infiltrating lymphocytes (TILs) as predictive biomarker for hormone receptor status, proliferative activity and clinical outcome in Her2-positive breast cancer. Appl Sci. 2021, 11:6788.","journal-title":"Appl Sci"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2017.46","article-title":"Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016","volume":"30","author":"Lugli A","year":"2017","unstructured":"Lugli A, Kirsch R, Ajioka Y, et al.. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Mod Pathol. 2017, 30:1299-311. 10.1038\/modpathol.2017.46","journal-title":"Mod Pathol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2017.10.003","article-title":"Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: a report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer","volume":"52","author":"Dieci MV","year":"2018","unstructured":"Dieci MV, Radosevic-Robin N, Fineberg S, et al.. Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: a report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. Semin Cancer Biol. 2018, 52:16-25. 10.1016\/j.semcancer.2017.10.003","journal-title":"Semin Cancer Biol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2014.01.004","article-title":"New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape","volume":"27","author":"Mittal D","year":"2014","unstructured":"Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape. Curr Opin Immunol. 2014, 27:16-25. 10.1016\/j.coi.2014.01.004","journal-title":"Curr Opin Immunol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/390512-tumor-infiltrating-lymphocytes-and-tumor-budding-emerging-prognostic-markers-in-breast-cancer","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T06:06:01Z","timestamp":1762495561000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/390512-tumor-infiltrating-lymphocytes-and-tumor-budding-emerging-prognostic-markers-in-breast-cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":27,"URL":"https:\/\/doi.org\/10.7759\/cureus.96266","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,6]]}}}